Cancer Letters
Volume 252, Issue 1 , Pages 43-54 , 8 July 2007

In vitro and in vivo anti-tumor effects of Astragalus membranaceus

  • William C.S. Cho

      Affiliations

    • Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong SAR, People’s Republic of China
    • Corresponding Author InformationCorresponding author. Tel.: +852 2958 5441; fax: +852 2958 5455.
    • ,
  • Kwok N. Leung

      Affiliations

    • Department of Biochemistry, The Chinese University of Hong Kong, Hong Kong SAR, People’s Republic of China

Received 5 September 2006 ,Revised 29 November 2006 ,Accepted 1 December 2006.

References 

  1. Cha RJ, Zeng DW, Chang QS. Non-surgical treatment of small cell lung cancer with chemo-radio-immunotherapy and traditional Chinese medicine. Zhonghua Nei Ke Za Zhi. 1994;33:462–466
  2. Treasure J. Herbal medicine and cancer: an introductory overview. Semin. Oncol. Nurs. 2005;21:177–183
  3. Chu DT, Wong WL, Mavligit GM. Immunotherapy with Chinese medicinal herbs I. Immune restoration of local xenogeneic graft-versus-host reaction in cancer patients by fractionated Astragalus membranaceus in vitro. J. Clin. Lab. Immunol. 1988;25:119–123
  4. Duan P, Wang ZM. Clinical study on effect of Astragalus in efficacy enhancing and toxicity reducing of chemotherapy in patients of malignant tumor. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2002;22:515–517
  5. Zou YH, Liu XM. Effect of Astragalus injection combined with chemotherapy on quality of life in patients with advanced non-small cell lung cancer. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2003;23:733–735
  6. Dong JC, Dong XH. Comparative study on effect of Astragalus injection and interleukin-2 in enhancing anti-tumor metastasis action of dendrite cells. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2005;25:236–239
  7. McCulloch M, See C, Shu XJ, Broffman M, Kramer A, Fan WY, et al. Astragalus-based Chinese herbs and platinum-based chemotherapy for advanced non-small-cell lung cancer: meta-analysis of randomized trials. J. Clin. Oncol. 2006;24:419–430
  8. Philip HJ. Dye exclusion test for cell viability. In:  Kruse PF,  Patterson MK editor. Tissue Culture Methods and Applications. New York: Academic Press; 1973;p. 406–408
  9. Gervais F, Martel RR, Skamene E. The effect of the non-steroidal anti-inflammatory drug Etodolac on macrophage migration in vitro and in vivo. J. Immunopharmacol. 1984;6:205–210
  10. Kaminuteski NE, Roberts JF, Guthrie FE. A rapid spectrophotometric method for assessing macrophage phagocytic activity. Immunol. Lett. 1985;10:329–331
  11. Ruffmann R, Welker RD, Saito T, Chirigos MA, Varesio L. In vivo activation of macrophages but not natural killer cells by picolinic acid (PLA). J. Immunopharmacol. 1984;6:291–304
  12. Hay H, Cohen J. Studies on the specificity of the L929 cell bioassay for the measurement of tumour necrosis factor. J. Clin. Lab. Immunol. 1989;29:151–155
  13. Choy YM, Leung KN, Cho WC, Wong CK, Pang PK. Immunopharmacological studies of low molecular weight polysaccharide fromAngelica sinensis. Am. J. Clin. Med. 1994;22:137–145
  14. Nanba H, Mori K, Toyomasu T, Kuroda H. Antitumor action of shiitake (Lentinus edodes) fruit bodies orally administered to mice. Chem. Pharm. Bull. (Tokyo). 1987;35:2453–2458
  15. Yoshida J, Takamura S, Yamaguchi N, Ren LJ, Chen H, Koshimura S, et al. Antitumor activity of an extract of Cordyceps sinensis (Berk.) Sacc. against murine tumor cell lines. Jpn. J. Exp. Med. 1989;59:157–161
  16. Ebina T, Murata K. Antitumor effect of PSK at a distant site: inductions of interleukin-8-like factor and macrophage chemotactic factor in murine tumor. Jpn. J. Cancer Res. 1990;81:1307–1313
  17. Torisu M, Hayashi Y, Ishimitsu T, Fujimura T, Iwasaki K, Katano M, et al. Significant prolongation of disease-free period gained by oral polysaccharide K (PSK) administration after curative surgical operation of colorectal cancer. Cancer Immunol. Immunother. 1990;31:261–268
  18. Lee KY, Jeon YJ. Macrophage activation by polysaccharide isolated from Astragalus membranaceus. Int. Immunopharmacol. 2005;5:1225–1233
  19. Wang JZ, Ito H, Shimura K. Enhancing effect of antitumor polysaccharide from Astragalus or Radix hedysarum on C3 cleavage production of macrophages in mice. Jpn. J. Pharmacol. 1989;51:432–434
  20. Hou YT, Ma GL, Wu SH, Li YY, Li HT. Effect of Radix Astragali seu Hedysari on the interferon system. Chin. Med. J. (Engl.). 1981;94:35–40
  21. Pace JL, Russell SW. Activation of mouse macrophages for tumor cell killing. I. Quantitative analysis of interactions between lymphokine and lipopolysaccharide. J. Immunol. 1981;126:1863–1867
  22. Beutler B. Cachexia: a fundamental mechanism. Nutr. Rev. 1988;46:369–373
  23. Albertini MR, Sondel PM. Tumor immunol.. In:  Ram BP,  Harris MC,  Tyle P editor. Immunology: Clinical, Fundamental, and Therapeutic Aspects. New York: VCH Publishers; 1990;p. 228–248
  24. Balkwill FR, Naylor MS, Malik S. Tumour necrosis factor as an anticancer agent. Eur. J. Cancer. 1990;26:641–644
  25. Haranaka K, Satomi N, Sakuai A, Haranaka R, Okada N, Kobayashi M. Antitumor activities and tumor necrosis factor producibility of traditional Chinese medicines and crude drugs. Cancer Immunol. Immunother. 1985;20:1–5
  26. Wang RT, Shan BE, Li QX. Extracorporeal experimental study on immuno-modulatory activity of Astragalus membranaceus extract. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2002;22:453–456
  27. Zhao KW, Kong HY. Effect of Astragalus on secretion of tumor necrosis factors in human peripheral blood mononuclear cells. Zhongguo Zhong Xi Yi Jie He Za Zhi. 1993;13:259;263–265
  28. Semenzato G. Lymphokine activated killer cells: a new approach to immunotherapy of cancer. Leukemia. 1990;4:71–80
  29. Chu DT, Lepe-Zuniga JL, Wong WL, LaPushin R, Mavligit GM. Fractionated extract of Astragalus membranaceus, a Chinese medicinal herb, potentiates LAK cell cytotoxicity generated by a low dose of recombinant interleukin-2. J. Clin. Lab. Immunol. 1988;26:183–187
  30. Chu D, Sun Y, Lin J, Wong W, Mavligit GM. F3, a fractionated extract of Astragalus membranaceus, potentiates lymphokine-activated killer cell cytotoxicity generated by low-dose recombinant interleukin-2. Zhong Xi Yi Jie He Za Zhi. 1990;10:34–36
  31. Chu DT, Lin JR, Wong W. The in vitro potentiation of LAK cell cytotoxicity in cancer and aids patients induced by F3 – a fractionated extract of Astragalus membranaceus. Zhonghua Zhong Liu Za Zhi. 1994;16:167–171
  32. Zhao TH. Positive modulating action of shengmaisan with Astragalus membranaceus on anti-tumor activity of LAK cells. Zhongguo Zhong Xi Yi Jie He Za Zhi. 1993;13:453;471–472
  33. Wang Y, Qian XJ, Hadley HR, Lau BH. Phytochemicals potentiate interleukin-2 generated lymphokine-activated killer cell cytotoxicity against murine renal cell carcinoma. Mol. Biother. 1992;4:143–146
  34. Lau BH, Ruckle HC, Botolazzo T, Lui PD. Chinese medicinal herbs inhibit growth of murine renal cell carcinoma. Cancer Biother. 1994;9:153–161
  35. Hozumi M. Fundamentals of chemotherapy of myeloid leukemia by induction of leukemia cell differentiation. Adv. Cancer Res. 1983;38:121–169
  36. Collins SJ, Bodner A, Ting R, Gallo RC. Induction of morphological and functional differentiation of human promyelocytic leukemia cells (HL-60) by compounds which induce differentiation of murine leukemia cells. Int. J. Cancer. 1980;25:213–218
  37. Ruscetti F, Sing G, Burke P, Bettens F, Schlick E, Ruscetti S, et al. Role of biologic response modifiers in the growth and differentiation of myeloid leukemic cells. Curr. Top. Microbiol. Immunol. 1989;149:165–172
  38. Cheng XD, Hou CH, Zhang XJ, Xie HY, Zhou WY, Yang L, et al. Effects of Huangqi (Hex) on inducing cell differentiation and cell death in K562 and HEL cells. Acta Biochim. Biophys. Sin. (Shanghai). 2004;36:211–217
  39. Alexander P. The functions of the macrophage in malignant disease. Ann. Rev. Med. 1976;27:207–224

PII: S0304-3835(06)00666-5

doi: 10.1016/j.canlet.2006.12.001

Cancer Letters
Volume 252, Issue 1 , Pages 43-54 , 8 July 2007

Article Tools

* Image Usage & Resolution